Route to three-dimensional fragments using diversity-oriented synthesis

被引:230
作者
Hung, Alvin W. [1 ]
Ramek, Alex [2 ]
Wang, Yikai [2 ]
Kaya, Taner [1 ]
Wilson, J. Anthony [1 ]
Clemons, Paul A. [1 ]
Young, Damian W. [1 ]
机构
[1] Broad Inst Harvard & Massachusetts Inst Technol, Chem Biol Program, Cambridge Ctr 7, Cambridge, MA 02142 USA
[2] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA
关键词
library development; probe discovery; DRUG DISCOVERY; LEAD DISCOVERY; SMALL MOLECULES; DESIGN; METATHESIS; STRATEGY; INHIBITORS; CHEMISTRY;
D O I
10.1073/pnas.1015271108
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chemical ligands as starting points for drug-discovery pursuits. The increasing number of clinical candidate drugs developed using FBDD approaches is a testament of the efficacy of this approach. The success of fragment-based methods is highly dependent on the identity of the fragment library used for screening. The vast majority of FBDD has centered on the use of sp2-rich aromatic compounds. An expanded set of fragments that possess more 3D character would provide access to a larger chemical space of fragments than those currently used. Diversity-oriented synthesis (DOS) aims to efficiently generate a set of molecules diverse in skeletal and stereochemical properties. Molecules derived from DOS have also displayed significant success in the modulation of function of various "difficult" targets. Herein, we describe the application of DOS toward the construction of a unique set of fragments containing highly sp3-rich skeletons for fragment-based screening. Using cheminformatic analysis, we quantified the shapes and physical properties of the new 3D fragments and compared them with a database containing known fragment-like molecules.
引用
收藏
页码:6799 / 6804
页数:6
相关论文
共 39 条
[1]   High-throughput crystallography for lead discovery in drug design [J].
Blundell, TL ;
Jhoti, H ;
Abell, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :45-54
[2]   A planning strategy for diversity-oriented synthesis [J].
Burke, MD ;
Schreiber, SL .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2004, 43 (01) :46-58
[3]   Fragment-based lead discovery: leads by design [J].
Carr, RAE ;
Congreve, M ;
Murray, CW ;
Rees, DC .
DRUG DISCOVERY TODAY, 2005, 10 (14) :987-992
[4]   From fragment to clinical candidate-a historical perspective [J].
Chessari, Gianni ;
Woodhead, Andrew J. .
DRUG DISCOVERY TODAY, 2009, 14 (13-14) :668-675
[5]   Fragment-based approaches to enzyme inhibition [J].
Ciulli, Alessio ;
Abell, Chris .
CURRENT OPINION IN BIOTECHNOLOGY, 2007, 18 (06) :489-496
[6]   Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles [J].
Clemons, Paul A. ;
Bodycombe, Nicole E. ;
Carrinski, Hyman A. ;
Wilson, J. Anthony ;
Shamji, Alykhan F. ;
Wagner, Bridget K. ;
Koehler, Angela N. ;
Schreiber, Stuart L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (44) :18787-18792
[7]   A rule of three for fragment-based lead discovery? [J].
Congreve, M ;
Carr, R ;
Murray, C ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2003, 8 (19) :876-877
[8]   Recent developments in fragment-based drug discovery [J].
Congreve, Miles ;
Chessari, Gianni ;
Tisi, Dominic ;
Woodhead, Andrew J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) :3661-3680
[9]   Drugging challenging targets using fragment-based approaches [J].
Coyne, Anthony G. ;
Scott, Duncan E. ;
Abell, Chris .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (03) :299-307
[10]   Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery [J].
Fink, Tobias ;
Reymond, Jean-Louis .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (02) :342-353